RBD-7022
- Generic Name
- RBD-7022
Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol
Phase 2
Not yet recruiting
- Conditions
- Primary Hypercholesterolemia or Mixed Hyperlipidemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT06750341
A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Suzhou Ribo Life Science Co. Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05912296
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath